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Abstract
Iron-deficiency anemia is a potent stimulator of the phosphaturic hormone Fibroblast 
growth factor-23 (FGF23). Anemia, elevated FGF23, and elevated serum phosphate 
are significant mortality risk factors for patients with chronic kidney disease (CKD). 
However, the contribution of anemia to overall circulating FGF23 levels in CKD 
is not understood. Our goal was to investigate the normalization of iron handling 
in a CKD model using the erythropoiesis stimulating agents (ESAs) Erythropoietin 
(EPO) and the hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) 
FG-4592, on the production of, and outcomes associated with, changes in bioactive, 
intact FGF23 (“iFGF23”). Our hypothesis was that rescuing the prevailing anemia in 
a model of CKD would reduce circulating FGF23. Wild-type mice were fed an ade-
nine-containing diet to induce CKD, then injected with EPO or FG-4592. The mice 
with CKD were anemic, and EPO improved red blood cell indices, whereas FG-4592 
increased serum EPO and bone marrow erythroferrone (Erfe), and decreased liver 
ferritin, bone morphogenic protein-6 (Bmp-6), and hepcidin mRNAs. In the mice 
with CKD, iFGF23 was markedly elevated in control mice but was attenuated by 
>70% after delivery of either ESA, with no changes in serum phosphate. ESA treat-
ment also reduced renal fibrosis markers, as well as increased Cyp27b1 and reduced 
Cyp24a1 mRNA expression. Thus, improvement of iron utilization in a CKD model 
using EPO and a HIF-PHDi significantly reduced iFGF23, demonstrating that ane-
mia is a primary driver of FGF23, and that management of iron utilization in patients 
with CKD may translate to modifiable outcomes in mineral metabolism.
K E Y W O R D S
CKD, EPO, FGF-23, HIF-PHDi, phosphate
2 of 8 |   NOONAN et Al.
1 |  INTRODUCTION
Chronic kidney disease (CKD) is the most prevalent form of 
combined phosphate and iron handling defects. With declin-
ing renal mass, patients with CKD lose the ability to produce 
erythropoietin (EPO) and develop anemia due to low blood 
iron, inflammation, hemorrhage, EPO resistance, or relative 
EPO deficiency. Recombinant human EPO has become a 
central replacement therapy for a large number of patients 
with CKD, but despite improving anemia, patients with a 
higher targeted hemoglobin had more adverse events (Drueke 
et  al.,  2006). A new class of drugs, hypoxia-inducible fac-
tor prolyl hydroxylase inhibitors (HIF-PHDi) was developed 
to increase endogenous EPO while the kidney retains some 
functional capacity during CKD (Maxwell & Eckardt, 2016). 
HIF-PHDi reduce the turnover of HIF1α and HIF2α tran-
scription factors, with HIF2α driving kidney EPO production 
(Wiesener et al., 2003).
A key portion of the systemic response to reduce serum 
phosphate in CKD is to elevate bone-produced bioactive, 
intact FGF23 (“iFGF23”). FGF23 acts through its co-re-
ceptor αKlotho (KL) and fibroblast growth factor receptors 
(FGFRs) to decrease renal phosphate reabsorption (Kurosu 
et al., 2006). During CKD progression, with loss of renal 
mass and low KL expression, serum FGF23 steadily in-
creases (Isakova, Wahl, et al., 2011). The marked increase 
in FGF23 during CKD goes beyond phosphate, as it was 
demonstrated in a mouse model of autosomal dominant hy-
pophosphatemic rickets (ADHR) that iFGF23 was elevated 
during iron-deficiency anemia in the genetic background of 
an Fgf23 stabilizing mutation (Farrow et al., 2011). It was 
also shown in non-dialysis patients with CKD that circu-
lating FGF23 is associated with anemia (Nam et al., 2018). 
These findings suggest that there is crosstalk between 
phosphate and iron homeostasis via FGF23, a critical rela-
tionship since elevated FGF23 is associated with a > 6-fold 
increased odds for CKD patient death (Isakova, Xie, et al., 
2011).
The prevailing elevation of FGF23 in CKD is associated 
with marked endocrine disease. In this regard, increased 
FGF23 downregulates the renal anabolic vitamin D 1α-hy-
droxylase (Cyp27b1) and upregulates the catabolic vitamin 
D 24-hydroxylase (Cyp24a1) which lowers circulating active 
1,25(OH)2 vitamin D (1,25D) (Shimada et  al.,  2001). The 
reduction in 1,25D results in hyperparathyroidism and sub-
sequent metabolic bone disease, which can be severe. The 
modulation of FGF23 may improve patient outcomes, as an 
iFGF23 reduction of 30% in patients with CKD using a calci-
mimetic during the EVOLVE trial was associated with reduc-
ing both adverse vascular outcomes and all-cause mortality 
(Moe et al., 2015). Thus reducing FGF23 in CKD to a level 
that does not induce hyperphosphatemia may provide critical 
ancillary benefit.
The role of iron utilization in driving FGF23 production 
appears somewhat paradoxical. Indeed, anemia clearly stim-
ulates FGF23 mRNA production in bone in mice and humans 
with ADHR (Farrow et al., 2011; Imel et al., 2011). This re-
lationship is underscored by the fact that oral iron supple-
mentation to patients with ADHR normalized the elevated 
FGF23 and cured the prevailing hypophosphatemia (Imel 
et  al.,  2019). In contrast, certain types of intravenous iron 
preparations, such as those with carboxymaltose backbones, 
increase iFGF23, potentially through the interruption of nor-
mal FGF23 inactivation by intracellular protease cleavage 
(Wolf, Koch, & Bregman, 2013). Thus, both iron and anemia 
regulate the bioactive form of this hormone under specific 
conditions. We and others found that EPO and the HIF-PHDi 
FG-4592 raised FGF23 production in vitro and in vivo when 
given acutely (Clinkenbeard et al., 2017; David et al., 2016; 
Hanudel, Eisenga, et al., 2018); however, the effects of these 
therapeutic agents on circulating FGF23 concentrations 
during anemia, and its downstream effects on mineral metab-
olism, are unknown. Herein, we showed in an anemic CKD 
model that treatment with EPO and the HIF-PHDi FG-4592 
improved iron utilization, and in parallel reduced iFGF23 and 
restored the balance of genes that control 1,25D production. 
Thus, careful management of anemia could provide import-
ant, modifiable outcomes for mineral metabolism in the CKD 
patient population.
2 |  MATERIALS AND METHODS
2.1 | Animal studies
Animal studies were approved by, and performed accord-
ing to the Institutional Animal Care and Use Committee 
(IACUC) of the Indiana University School of Medicine, and 
complied with the NIH guidelines for the use of animals in 
research. C57BL/6 female mice were purchased (Jackson 
Labs) and acclimated prior to study. Mice were euthanized 
by CO2 inhalation/cervical dislocation, and blood was col-
lected by cardiac puncture for serum and plasma (collected 
in EDTA tubes). Where indicated, mice were facial vein 
bled for interim analysis, collecting less than 5% of the total 
blood volume to mitigate potential effects on the parameters 
tested (Diehl et al., 2001). Red blood cell indices were meas-
ured on whole blood from tail bleeds using an Element HT5 
Veterinary Hematology Analyzer (Heska).
2.2 | Rodent diets and ESA treatments
The adenine diet model was used to induce kidney failure 
in wild-type mice, largely according to previous protocols 
(Clinkenbeard et al., 2019). Significant sex effects have been 
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shown with the provision of adenine-containing diets, there-
fore female mice were studied, as males rapidly succumb to the 
renal disease (Diwan, Small, Kauter, Gobe, & Brown, 2014). 
Mice were acclimated for 1 week and during this time fed nor-
mal rodent chow. At 8 weeks of age, mice were switched to a 
control casein-based diet (0.9% phosphate and 0.6% calcium, 
TD.150303 Envigo), or a 0.2% “run-in” adenine-containing 
diet (TD.160020; Envigo) for 4 weeks. Mice were provided a 
0.15% adenine “maintenance” diet (TD.150305; Envigo) after 
4  weeks. Two different treatment protocols were employed 
to study the impact of the ESAs EPO and HIF-PHDi. Mice 
receiving EPO (“EPO cohort”) were fed the adenine diet for 
12  weeks total (4  weeks of 0.2% adenine, then 8  weeks of 
0.15% adenine) to cause significant anemia. EPO injections 
(50 U/g, BioLegend) were given three times per week intra-
peritoneally (i.p.) starting at 6 weeks on the adenine diet. This 
dose was determined from previous reports of acute EPO in-
jections in the adenine CKD mouse model (Hanudel, Eisenga, 
et al., 2018; Hanudel, Rappaport, et al., 2018). In contrast, 
mice receiving the HIF-PHDi FG-4592 (“FG cohort”) were 
tested on a shortened time course and were on the adenine diet 
for 9 weeks total (4 weeks of 0.2% adenine, then 5 weeks of 
0.15% adenine) to ensure the mice with CKD were anemic but 
the kidneys were viable enough to produce endogenous EPO 
in response to a HIF-PHDi dose comparable to other rodent 
studies (Beck, Henschel, Chou, Lin, & Del Balzo, 2017; Kabei 
et al., 2020; Seeley, Sternlicht, Klaus, Neff, & Liu, 2017). FG-
4592 injections (Roxadustat, SelleckChem; 70 mg/kg) were 
given i.p. three times over the last 5 days of the study. Diets 
and water were provided ad libitum.
2.3 | Serum biochemical parameters
Routine serum biochemical parameters were determined 
using an automated COBAS MIRA Plus Chemistry Analyzer 
(Roche Diagnostics). Serum iFGF23 was assessed using a ro-
dent-specific commercial ELISA for bioactive, intact FGF23 
(“iFGF23”; Quidel, Inc). Serum EPO was measured using 
the Mouse Epo Quantikine ELISA (R&D Systems).
2.4 | RNA preparation and quantitative RT-
PCR (qPCR)
Kidney, liver, and bone marrow flushed from long bones 
were harvested and homogenized in 1 ml of Trizol reagent 
(Invitrogen/ThermoFisher Scientific) according to the manu-
facturer's protocol, then further purified using the RNeasy Kit 
(Qiagen, Inc). RNA samples were tested with intron-span-
ning primers specific for mouse vitamin D 1α-hydroxylase 
(Cyp27b1), vitamin D 24-hydroxylase (Cyp24a1), type 1 
collagen (Col1a1), type 3 collagen (Col3a1), erythroferrone 
(Erfe, Fam132b), ferritin (Fth1), bone morphogenetic pro-
tein-6 (Bmp6), interleukin-6 (IL-6), and hepcidin (Hamp) 
mRNAs; Gapdh was used as an internal control for RT-qPCR 
(Applied Biosystems/ThermoFisher Scientific). The TaqMan 
One-Step RT-PCR kit was used to perform the qPCR reac-
tions under cycling conditions: 30 min 48°C, 10 min 95°C, 
followed by 40 cycles of 15  s 95°C and 1  min 60°C. The 
data were collected using a StepOne Plus system (Applied 
Biosystems/ThermoFisher Scientific). The expression levels 
of mRNAs were calculated relative to appropriate littermate 
diet controls, and data analyzed by the 2−∆∆CT method (Livak 
& Schmittgen, 2001).
2.5 | Statistical analysis
Data were analyzed by two-way ANOVA, followed by a Tukey 
post hoc test or Student's t test (two-tailed). Significance for 
all tests was set at p < .05. Data are represented as box-and-
whisker plots with the middle line representing the median of 
the data, upper and lower quartiles within the boxes, and the 
whiskers as the minimum and maximum.
3 |  RESULTS
The primary use of the erythropoiesis stimulating agents 
(ESAs) EPO and HIF-PHDi is to treat the anemia of CKD. 
Cohorts of wild-type mice were provided an adenine-
containing diet to induce CKD as we previously described 
(Clinkenbeard et  al.,  2019), and were then treated with ei-
ther recombinant human EPO (“EPO” cohort) or the HIF-
PHD inhibitor FG-4592 (“FG” cohort). Mice with CKD in 
the EPO cohort treated with saline had significantly elevated 
creatinine and blood urea nitrogen (BUN) compared with 
control-diet fed mice treated with saline, indicating renal 
disease induction (Table 1). Similar to patients with CKD, 
serum phosphorous was significantly elevated in the CKD-
saline group, and EPO treatment did not cause a significant 
difference to these levels (Table 1, EPO cohort). In the FG-
4592 cohort, BUN was elevated in mice with CKD compared 
with mice fed the casein diet (Table  1, FG cohort). There 
was no significant difference in serum creatinine, calcium, 
or phosphorous with either diet administration or drug treat-
ment (Table 1, FG cohort). Analysis of red blood cell indices 
in the EPO cohort showed that the CKD-saline mice were 
anemic with significantly lower RBC, HB, HCT, and MCV. 
EPO significantly increased these parameters in both casein 
control and CKD mice (Table 1, EPO cohort).
The FG-4592 CKD cohort also had anemia prior to FG-
4592 treatment. FG-4592 treatment rescued MCHC to con-
trol levels but did not significantly alter any other red blood 
cell parameters (Table  1, FG cohort). The EPO treatment 
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significantly increased total serum iron in both control and 
CKD mice (Table 1, EPO cohort). In contrast, serum iron was 
reduced following acute FG-4592 treatment in the control and 
CKD mice (Table 1, FG cohort) potentially due to increased 
iron utilization by stimulated erythropoiesis. We also observed 
that FG-4592 significantly elevated serum EPO concentrations 
in both the diet-control mice and the CKD group (Figure 1a). 
Additionally, FG-4592 significantly elevated bone marrow 
erythroferrone (Erfe) mRNA expression, an EPO-responsive 
hormone (Figure 1b). To address whether rapid changes in iron 
utilization occurred with FG-4592 treatment, liver iron mark-
ers were assessed. Ferritin H (Fth1) mRNA expression was 
reduced in both control and CKD mice treated with FG-4592 
(Figure 1c). This reduction was associated with decreased liver 
Bmp-6 (Figure 1d and hepcidin (Hamp) (Figure 1e) gene ex-
pression in both control and CKD groups, linking enhanced 
erythropoiesis with iron utilization. This was also associated 
with a trend toward reduced liver IL-6 mRNA expression 
(Figure 1f). One of the pathogenic manifestations of CKD is 
the progressive and irreversible renal fibrosis inducing kidney 
damage (Duffield,  2014). We assessed whether EPO, previ-
ously described to alleviate renal fibrosis in CKD (Geng, Hu, 
& Lian, 2015), and FG-4592, could impact markers associated 
with renal fibrosis, including type I (Col1a1) and type III colla-
gen (Col3a1). Both Col1a1 (Figure 1g) and Col3a1 (Figure 1h) 
mRNAs were significantly elevated in the mice with CKD, and 
EPO and FG-4592 reduced their expression.
Similar to patients with CKD, blood iFGF23 rose pro-
gressively in the mice with CKD prior to ESA treatment, 
and continued to increase in the saline-treated CKD mouse 
groups. The EPO administration in the control diet group had 
no effect on serum iFGF23. In stark contrast, iFGF23 was 
reduced by > 70% upon EPO treatment of the CKD cohort 
(Figure 2a). FG-4592 treatment raised iFGF23 in mice fed 
the casein diet; however, there was no statistically significant 
difference when compared with saline-treated mice receiving 
the same diet. In a manner similar to the CKD-EPO-treated 
mice, the mice with CKD in the FG-4592 cohort had reduced 
levels of iFGF23 by over 70% at the end of the treatment 
period (Figure 2b). Therefore, the anemia of CKD is a potent 
stimulator of FGF23, as improvement of iron utilization via 
exogenous EPO administration, or endogenous EPO stimula-
tion in mice treated with a HIF-PHDi, markedly attenuated 
the increase in circulating iFGF23 concentrations.
Patients with CKD can have aberrant 1,25D production, 
due in part to the actions of elevated iFGF23 on the kidney 
(Mehrotra et al., 2009). To determine the downstream effects 
of lowered iFGF23 on 1,25D metabolism, kidney Cyp27b1 
and Cyp24a1 gene expression was measured, and showed that 
although modestly elevated, there was no statistical difference 
in Cyp27b1 expression between casein-saline and CKD-saline 
groups; EPO treatment significantly elevated Cyp27b1 ex-
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the prevailing elevated iFGF23, Cyp24a1 mRNA was signifi-
cantly increased in the CKD group, whereas EPO treatment had 
a trend toward reduced expression in these mice (Figure 2d). 
Similarly, FG-4592 treatment significantly increased Cyp27b1 
in both the casein and CKD groups (Figure 2e). Further, the 
elevated Cyp24a1 was attenuated with FG-4592 treatment 
(Figure 2f). Taken together, these data support the proposition 
that the changes that occur in 1,25D metabolism during CKD 
may be reversible by therapeutics targeting defective iron han-
dling, potentially through lowering FGF23, but not to levels 
that could cause further increases in serum phosphate.
4 |  DISCUSSION
Anemia and elevated FGF23 are each highly associated with 
poor outcomes in patients with CKD, including increased 
odds for death and severe morbidity. Our goal was to test the 
correction of anemia and iron utilization on FGF23 produc-
tion and its impact on mineral metabolism. Collectively, our 
data using two distinct therapeutic agents, namely EPO and 
FG-4592, showed that both extended and acute reversal of 
anemia-related manifestations in a model of CKD, respec-
tively, were associated with a marked lowering of iFGF23. 
Consistent with known patient outcomes (Drueke et al., 2006; 
Pfeffer et  al.,  2009), an extended treatment with EPO in-
creased hemoglobin levels in both CKD and control mice. 
Although our acute treatment protocol with FG-4592 did not 
rescue hemoglobin levels or red blood cell production in the 
mice with CKD, this agent stimulated endogenous EPO pro-
duction. Indeed, we did observe significantly elevated plasma 
EPO in control and CKD mice treated with FG-4592, leading 
to increased bone marrow expression of Erythroferrone (Erfe). 
We also observed reduction of liver Bmp-6, hepcidin, and fer-
ritin mRNAs, which were consistent with EPO-mediated Erfe 
production. Increased serum phosphate is associated with sig-
nificant detrimental effects on CKD patients, including wors-
ening of vascular calcifications leading to cardiac disease 
(Adeney et  al.,  2009; McGovern et  al.,  2013). Importantly, 
in the mice with CKD and treated with EPO or FG-4592, 
despite the > 70% reduction in iFGF23 blood phosphate did 
not increase, and a restoration of kidney 1,25D metabolizing 
F I G U R E  1  Iron utilization parameters and markers of renal fibrosis in CKD mice treated with ESAs. (a) Mice treated with FG-4592 had 
markedly elevated serum EPO in both casein and CKD mice. (b) Bone marrow Erythroferrone (Erfe) expression was significantly elevated in both 
normal and CKD mice treated with FG-4592. (c) Liver ferritin (Fth1) mRNA expression was reduced with FG-4592 treatment in both casein and 
CKD groups. (d) Liver Bmp-6 and (e) Hepcidin expression was decreased in both control and CKD mice with FG treatment, and was reduced in 
saline-CKD mice compared to casein controls. (f) Liver IL-6 trended toward being reduced with FG-4592 treatment in normal and CKD mice. (g) 
Fibrosis marker Col1a1 was significantly elevated in CKD-saline mice in both the EPO and FG cohorts; treatment with either EPO or FG-4592 
significantly reduced expression. (h) Similarly, Col3a1 was upregulated in CKD-saline mice in both groups and was significantly reduced with 
ESA treatment (n = 3–8 mice per group; *p < .05; **p < .01 versus treatment, same diet; #p < .05; ##p < .01 versus diet, same treatment via two-
way ANOVA with a Tukey post hoc test)
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enzymes was observed. The difference in iFGF23 from peak 
elevated levels to the reduced concentrations following EPO 
and FG-4592 treatments could reflect the “iron/anemia sen-
sitive” portion of iFGF23 production during CKD. Despite 
this marked lowering, circulating iFGF23 concentrations re-
mained well above normal physiological levels. Therefore 
this remaining proportion of iFGF23 could collectively reflect 
additional stimulators of FGF23 in CKD, such as hyperphos-
phatemia, inflammation, and PTH among others.
Strengths of this work included using the adenine model of 
CKD that displayed associated anemia as well as the known 
human phosphate-related phenotypes. This model responded 
similarly to clinical therapeutics, including direct EPO injec-
tion and HIF-PHDi, which completely rescued the prevail-
ing anemia and acutely improved markers of iron handling, 
respectively. In this regard, with EPO treatment, red blood 
cell indices were returned to normal ranges. Whereas patients 
with CKD receiving EPO can have low serum iron requiring 
supplementation, it is possible herein that the elevated serum 
iron we observed in the CKD-EPO group was potentially 
due to inhibiting further erythropoiesis and limiting iron 
utilization since a polycythemic state was reached. Another 
F I G U R E  2  Effect of treatments on iFGF23 and 1,25D-regulating enzyme expression. (a) Intact FGF23 (iFGF23) in the EPO cohort was 
markedly elevated in CKD-saline mice compared to the casein control diet mice. EPO administration in the casein diet group had no effect on 
FGF23 compared to saline-injected mice. Importantly, iFGF23 was lowered in CKD mice treated with EPO by over 70%. (b) In the FG cohort, 
the adenine diet induced iFGF23, which remained elevated in saline-treated mice. FG-4592 (“FG”) treatment in CKD mice significantly reduced 
iFGF23 levels by over 70% compared to saline controls. The dashed line in each graph indicates where diet was switched from 0.2% adenine to 
0.15% adenine for the remainder of the study. The shaded area indicates the treatment window with either EPO or FG-4592. (c) In the EPO-treated 
cohort, renal Cyp27b1 mRNA remained unchanged in mice with CKD compared to casein controls, and EPO treatment significantly induced its 
expression. (d) Cyp24a1 mRNA was increased in mice with CKD compared with controls, and there was no significant difference in expression 
in the EPO-CKD mice. (e) In the FG-4592 treated cohort, Cyp27b1 mRNA was significantly elevated with FG-4592 treatment in both diets with 
no difference between the diets. (f) Cyp24a1 expression was elevated in the mice with CKD, and this was reduced to control levels with FG-4592 
treatment (n = 3–8 mice per group; *p < .05;**p < .01 CKD Saline versus Casein-Saline, #p < .05; ##p < .01 CKD-EPO/FG versus CKD Saline via 
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possibility is there could be stimulation of Erfe, leading to 
decreased hepcidin and increased iron absorption. In addi-
tion, FG-4592 treatment markedly induced serum EPO and 
corrected liver iron utilization markers in the CKD group. 
Although it is not clear whether the increase in serum iron or 
the combination of elevated iron and reversal of anemia sup-
pressed FGF23 in our study, it is likely that a major portion 
of the elevated FGF23 observed in the CKD mice could be 
attributed to defects in iron homeostasis. In a recent report, 
iron-deficient mice with CKD receiving acute high dose EPO 
had no changes in iFGF23 after 6 and 24 hr, whereas iFGF23 
was increased in normal, iron replete mice during the same 
timeframe (Hanudel, Eisenga, et al., 2018). Thus, the use of 
ESAs in the treatment of CKD may provide benefit in terms 
of mineral metabolism, as previous work using iron injec-
tions alone in a rat model of CKD did not have major effects 
on plasma FGF23 levels (Gravesen, Hofman-Bang, Mace, 
Lewin, & Olgaard,  2013). Although the aforementioned 
short-term EPO and FG-4592 in vitro and in vivo studies 
caused FGF23 increases in normal animals and cells, the re-
duction of circulating FGF23 by improving iron utilization in 
CKD supports that suppression of FGF23 over the long term 
is a stronger effect than the acute stimulatory ability of ESAs 
on FGF23 synthesis. Therefore, a potential ESA off-target ef-
fect of stimulating FGF23 production could be hypothesized. 
However, as a class these drugs may instead reduce FGF23 
and provide ancillary patient benefit, although long-term pro-
spective trials are needed to test this hypothesis.
Limitations of our studies included the fact that FG-4592 
delivery was relatively short term. This approach was under-
taken to assure that the mice with CKD would have suffi-
cient residual kidney function to produce EPO in response 
to this analog, in line with previous studies of HIF-PHDi. 
We found that the lower serum iFGF23 observed after FG-
4592 treatment was coincident with reduced liver ferritin and 
hepcidin mRNAs, as well as low serum iron. These results 
support the concept that even at very early stages of improv-
ing systemic iron utilization, FGF23 transcription, and cellu-
lar processing are sensitive to iron adaptation. Future work 
could focus upon performing longer term studies with EPO 
and HIF-PHDi to identify whether FGF23 suppression is 
indirect through tissue–tissue interactions, or whether iron/
oxygen content directly reduces anemia-driven FGF23 pro-
duction via suppression of HIF1-2α transcriptional activity 
in osteocytes. Additionally, this study was not designed to 
fully distinguish the effects of reduced iFGF23 levels in the 
context of increased EPO, therefore, conditional-deletion 
approaches could define EPO- and FGF23-specific targets. 
In summary, our work demonstrated that the major portion 
of elevated iFGF23 in CKD is likely due to the associated 
anemia/iron-deficiency, is therapeutically responsive to the 
control of iron utilization, and may thus provide modifiable 
patient benefit for mineral handling during CKD.
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